DYSPORT: payments to doctors
Payments that named DYSPORT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $6.4M
- Providers
- 12,408
- Transactions
- 40,554
- Average per transaction
- $159
The per-transaction average — $159 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 12,408 providers the average total is $520, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $4,808,286 | 74.6% |
| Ipsen Innovation | $782,549 | 12.1% |
| Galderma Laboratories, L.p. | $474,728 | 7.4% |
| Ipsen Pharma SAS | $189,220 | 2.9% |
| Ipsen Biopharm Limited | $102,286 | 1.6% |
| Ipsen Bioscience Inc | $82,588 | 1.3% |
| Saol Therapeutics Inc. | $9,181 | 0.1% |